R 170591Alternative Names: JNJ-2408068
Latest Information Update: 03 Oct 2007
$50 / €47 *
At a glance
- Originator Janssen L.P.
- Class Antivirals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 03 Oct 2005 Discontinued - Preclinical for Respiratory syncytial virus infections in Belgium (Inhalation)
- 05 May 2001 Preclinical development for Respiratory syncytial virus infections in Belgium (Inhalation)
- 05 May 2001 A preclinical study has been added to the Viral Infections antimicrobial activity and pharmacodynamics sections and the pharmacokinetics section